Investigation Report on China Cinepazide Market, 2010-2019
|発行||China Research and Intelligence||商品コード||338981|
|出版日||ページ情報||英文 20 Pages
|中国のシネパジド市場の分析 Investigation Report on China Cinepazide Market, 2010-2019|
|出版日: 2015年09月07日||ページ情報: 英文 20 Pages||
シネパジドの年間売上高は、4億人民元を超えています。現在、中国のシネパジド市場では、Beijing Hwellso Pharmaceutical Co., Ltd.が独占しています。
As a new generation of piperazine, cinepazide(cinepazide maleate) has been widely used in Europe and Japan. As calcium channel blocker, cinepazide can stop calcium from entering vascular smooth muscle cell and relax smooth muscle of cerebral vessel, coronary artery and peripheral vessel so as to relieve vasospasm, reduce vascular resistance, improve flexibility of red blood cell, increase blood circulation in cerebral vessel and improve microcirculation and brain metabolism. Cinepazide could also increase the number of cAMP by inhibiting cAMP phosphodiesterase and reduce oxygen consumption.
In Apr.2002, cinepazide of Beijing Hwellso Pharmaceutical Co., Ltd was approved to enter the market with two dosage forms of oral formulation and injection under the trade name of Kelinao. Currently, Kelinao is the only domestic brand for the treatment of cardiovascular diseases. And in 2009, cinepazide was included in the national medicare drug list.
Cinepazide maleate, after wide application, has gained the recognition of Chinese doctors and patients for the treatment of cerebral arteriosclerosis, transient ischemic attack, cerebral thrombosis, cerebral embolism, cerebral hemorrhage sequel and post-traumatic brain syndrome. Besides, due to its efficacy in cardiovascular diseases and peripheral vascular diseases, cinepazide maleate has become a leading product in cerebrovascular drug market. With ageing population, the number of cerebrovascular cases has kept rising, leading to a vast market for cinepazide.
According to CRI's market survey, the annual sales value of cinepazide in sample hospitals has remained over CNY 400 million. Currently, cinepazide market in China is dominated by Beijing Hwellso Pharmaceutical Co., Ltd.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: